Community Oncology

Volume 5, Number 11, Supplement 16 (November 2008)

Current Clinical Trials

1

  

SPIRITT: a study of second-line treatment of metastatic colorectal cancer with FOLFIRI plus panitumumab or bevacizumab

J. Randolph Hecht, MD, and Allen L. Cohn, MD

David Geffen School of Medicine at UCLA, Los Angeles, CA, and Rocky Mountain Cancer Center, Denver, CO

Regimens incorporating irinotecan, oxaliplatin, capecitabine, and bevacizumab have significantly improved survival in patients with metastatic colorectal cancer (mCRC). Most patients eventually progress, however, requiring second-line therapy. Inhibitors of the epidermal growth factor receptor (EGFR) have demonstrated efficacy in mCRC for certain patients. Panitumumab, a fully human monoclonal antibody, has demonstrated activity as a single agent in the treatment of mCRC, and clinical study data indicate some activity in combination with chemotherapy. SPIRITT (Second-line Panitumumab Irinotecan Treatment Trial) is an open-label, randomized, phase II study evaluating 5-fluorouracil, leucovorin, and irinotecan, administered every 2 weeks, in combination with either panitumumab or bevacizumab as second-line therapy for patients with mCRC after the failure of first-line treatment with oxaliplatin-based chemotherapy plus bevacizumab.

abstract full text 284 kb

© 2008 by Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher.

The opinions expressed herein are those of the authors or advertisers. The authors, editors, and publishers make every effort to ensure that no inaccurate or misleading data, opinion, or statement is published in this journal and that drug names, dosages, and recommendations are accurate. However, readers should confirm all dosage schedules against the manufacturer’s package information data. The Publisher, Editorial Board, and their employees accept no liability whatsoever for the consequences of any inaccurate or misleading data, opinion, or statement.